Measurement of Serum 1,25-dihydroxyvitamin D (calcitriol)
Customize your policy alerts
Sign up for Arizona Complete Health Policy CP.MP.152 alerts
Get alerted when Policy CP.MP.152 changes without checking for updates manually.
Monitor payer policy activity
Defines when measurement of serum 1,25(OH)2D (CPT 82652) is medically necessary versus not medically necessary for routine screening, for members of Arizona Complete Health (Centene-affiliated health plans). Affects ordering providers and billing for vitamin D testing.
No material clinical or coverage changes in this revision.
Coverage Criteria for Measurement of Serum 1,25(OH)2D
Medically necessary indications
Covered when ANY of the following indications are present (measurement of serum 1,25(OH)2D is medically necessary):
- Indication: Chronic kidney disease
- Indication: Hereditary phosphate-losing disorders
- Indication: Oncogenic osteomalacia
- Indication: Pseudovitamin D-deficiency rickets
- Indication: Vitamin D-resistant rickets
- Indication: Chronic granuloma-forming disorders (e.g., sarcoidosis and some lymphomas)
- Indication: Hyperparathyroidism
Not medically necessary
Not covered:
Measurement of serum 1,25(OH)2D for routine population screening is not medically necessary.
Measurement of serum 1,25(OH)2D (CPT 82652) for the purpose of routine screening of average‑risk, asymptomatic individuals is considered not medically necessary. This policy applies when testing is ordered solely for population or general screening without clinical indications that meet the covered criteria.
Measurement of serum 1,25(OH)2D for routine screening of average‑risk, asymptomatic persons is explicitly not medically necessary and therefore not covered. Providers should ensure testing is supported by one of the specified clinical indications before ordering CPT 82652.
Coding
| 82652 | Vitamin D; 1,25 dihydroxy, includes fraction(s), if performed |
| No codes listed |
| A15.0-A19.9 | Tuberculosis (ICD-10 range listed) |
| C81.00-C81.99 | Hodgkin lymphoma |
| C82.00-C82.99 | Follicular lymphoma |
| C83.00-C83.99 | Non-follicular lymphoma |
| C84.00-C84.99 | Mature T/NK-cell lymphomas |
| C88.0-C88.9 | Malignant immunoproliferative diseases and certain other B-cell lymphomas |
| D86.0-D86.9 | Sarcoidosis |
| E20.0 | Idiopathic hypoparathyroidism |
| E20.8 | Other hypoparathyroidism |
| E21.0-E21.5 | Hyperparathyroidism and other disorders of parathyroid gland |
Provider Actions and Billing Requirements
Prior Authorization / Coverage Headline
Measurement of serum 1,25(OH)2D (CPT 82652) is covered when billed with diagnoses supporting the listed indications; routine population screening of average-risk asymptomatic individuals is not covered.
- Covered when ordered for monitoring acquired or inherited disorders of vitamin D and phosphate metabolism, including but not limited to: chronic kidney disease; hereditary phosphate‑losing disorders; oncogenic osteomalacia; pseudovitamin D‑deficiency rickets; vitamin D‑resistant rickets; chronic granuloma‑forming disorders (e.g., sarcoidosis, some lymphomas); hyperparathyroidism.
- Routine screening for average‑risk, asymptomatic individuals is considered not medically necessary and will be denied.
Provider Guidance
Providers must include documentation in the medical record supporting the clinical indication for ordering CPT 82652. Submit relevant clinical notes, laboratory findings, and treatment history as needed to justify medical necessity.
- Include reason for test and relevant signs/symptoms or diagnosis in the chart.
- Attach supporting diagnosis codes from the ICD‑10 ranges listed below when submitting claims for CPT 82652.
Attach Supporting ICD-10 Diagnosis
Attach one or more of the following ICD‑10 diagnosis codes or ranges when billing CPT 82652 to support coverage under the indications above.
- A15.0–A19.9 (Tuberculosis)
- C81.00–C81.99, C82.00–C82.99, C83.00–C83.99, C84.00–C84.99, C88.0–C88.9 (Hodgkin and certain non‑Hodgkin lymphomas and related malignancies)
- D86.0–D86.9 (Sarcoidosis)
- E20.0, E20.8, E21.0–E21.5 (Hypoparathyroidism and hyperparathyroidism disorders)
- E55.0 (Rickets, active)
- E83.30–E83.39 (Disorders of phosphorus metabolism and phosphatases)
- E83.50–E83.59 (Disorders of calcium metabolism)
- E89.2 (Postprocedural hypoparathyroidism)
- M83.8–M83.9 (Adult osteomalacia)
- N18.1–N18.9 (Chronic kidney disease)
- N25.0, N25.81 (Renal osteodystrophy; secondary hyperparathyroidism of renal origin)
- P37.0 (Congenital tuberculosis)
Routine Screening Not Medically Necessary
Tests ordered for routine population screening of average‑risk, asymptomatic individuals are not medically necessary and are not covered. Claims for CPT 82652 billed without supporting diagnoses from the ranges above or without adequate documentation of clinical indication may be denied.
- Do not order CPT 82652 for general population screening or for asymptomatic patients without clinical risk factors.
- When denied, appeals must include clinical documentation demonstrating one of the covered indications.
Background
25‑hydroxyvitamin D [25(OH)D] is the major circulating form used to assess overall vitamin D status; by contrast, 1,25‑dihydroxyvitamin D [1,25(OH)2D] (calcitriol) is the hormonally active form that circulates at low concentrations and has a short half‑life. Measurement of 1,25(OH)2D is useful in selected acquired and inherited disorders of vitamin D and phosphate metabolism — for example, chronic kidney disease, hereditary phosphate‑losing disorders, oncogenic osteomalacia, pseudovitamin D‑deficiency rickets, vitamin D‑resistant rickets, chronic granuloma‑forming disorders (e.g., sarcoidosis and some lymphomas), and hyperparathyroidism — where assessment of the active metabolite informs diagnosis or management. Because 1,25(OH)2D does not reflect vitamin D reserves, it is not appropriate for routine population screening of asymptomatic, average‑risk individuals.
Definitions
Revision History
Policy developed (initial), with approval recorded in December 2017 and references reviewed and updated.
References reviewed and updated; corrected code E20.00 to E20.0 and updated approval date.
References reviewed and updated; terminology changed from 'member' to 'member/enrollee' throughout the policy and header labels adjusted; annual review performed.
Annual review with expansion of ICD-10 tuberculosis range to A15.0-A19.9 and addition of N25.81 to supporting diagnosis codes; header and revision log labels clarified; references reviewed and updated with specialist review.
Annual review; references reviewed and updated.
Annual review with addition of criteria I.G. Hyperparathyroidism and addition of ICD-10 codes E89.2, M83.8, and M83.9; internal and external specialist review and references updated.
Annual review; references reviewed and updated with external specialist review.
Annual review; references reviewed and updated with external specialist review.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.